AFT Pharmaceuticals Limited (NZX: AFT) Builds North American Momentum

Wednesday 23rd December 2020

AFT Pharmaceuticals today announces it is building momentum in the pivotal North American market with the appointment of Toronto-based Dr Ted Witek to the board and the launch of its Maxigesic pain relief medicine in Canada.

Dr Witek, an American professional director, healthcare advisor and academic, joins the board on 1 January 2021 as an independent non-executive director. He strengthens the board’s experience with North American pharmaceutical regulators and markets. His appointment is a recognition of the importance AFT attaches to its success in the North American market.

The launch of Maxigesic in Canada, under AFT’s Combogesic® brand, represents the company’s first foray into North America and opens the door to a Canadian analgesic market worth CAD$813 million.

See the links below for more details:

AFT builds North American momentum

Canadian release

Source: AFT Pharmaceuticals Limited

Comments from our readers

No comments yet